Integer (ITGR) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
8 Jul, 2026Executive summary
Q1 2025 sales rose 7% year-over-year to $437 million, with organic growth of 6% and strong demand from new product ramps and acquisitions.
Adjusted operating income increased 14% to $71 million; adjusted net income up 19% to $46 million; adjusted EPS grew 15% to $1.31.
GAAP net loss from continuing operations was $22.5 million, or $(0.66) per share, due to a $46.7 million debt conversion inducement expense.
CEO succession announced: Payman Khales to become CEO in October 2025, with Joseph Dziedzic staying as advisor through March 2026.
Completed acquisitions of Precision Coating and VSi Parylene, expanding proprietary coating capabilities.
Financial highlights
Q1 2025 sales reached $437 million, up 7% reported and 6% organic year-over-year; adjusted EBITDA was $92 million, up 14%.
Adjusted net income was $46 million, up 19% year-over-year; adjusted EPS was $1.31, up from $1.14 in Q1 2024.
Free cash flow improved to $6 million, up $12 million from prior year; cash flow from operations was $31 million, up 35%.
Net total debt at quarter-end was $1.23 billion, with leverage ratio at 3.3x trailing four-quarter adjusted EBITDA.
Capex spending in Q1 2025 was $25 million; 2025 capital expenditures expected at $110–$120 million.
Outlook and guidance
2025 sales outlook: $1.846–$1.88 billion, up 8–10% reported and 6–8% organic.
Adjusted EBITDA guidance: $401–$422 million (11–17% growth); adjusted operating income: $315–$331 million (11–16% growth).
Adjusted net income outlook raised to $218–$231 million (19–26% growth); adjusted EPS outlook raised to $6.15–$6.51, up 16–23%.
Free cash flow guidance increased to $120–$140 million for 2025, up 20–40% year-over-year.
Leverage ratio targeted at 2.5x–3.5x; adjusted effective tax rate expected at 19–21%.
Latest events from Integer
- Leadership transition set amid robust growth and minimal tariff impact, with strategy unchanged.ITGR
Bank of America 2025 Healthcare Conference9 Jul 2026 - 2025 outlook features robust organic growth, margin expansion, and enhanced vertical integration.ITGR
KeyBanc Annual Health Care Forum 20259 Jul 2026 - Double-digit 2024 growth, strategic acquisitions, and strong 2025 outlook with expanding margins.ITGR
Q4 20248 Jul 2026 - Strategic review and robust pipeline position the business for above-market growth by 2027.ITGR
Bank of America Global Healthcare Conference 20268 Jul 2026 - Strategic review underway; growth delayed to late 2026 amid EP market shifts and disciplined cost control.ITGR
Truist Securities MedTech Conference 202616 Jun 2026 - Temporary product headwinds in 2026 are expected to give way to above-market growth in 2027.ITGR
2026 KeyBanc Capital Markets Healthcare Forum12 May 2026 - 2026 outlook lowered on product headwinds; strategic review and share buybacks underway.ITGR
Q1 20261 May 2026 - 2025 saw 8% sales and 21% EPS growth; 2026 guidance is stable with strong long-term prospects.ITGR
Q4 20259 Apr 2026 - Annual meeting to vote on directors, auditor, executive pay, and new incentive plan amid strong 2025 results.ITGR
Proxy filing6 Apr 2026